MX2020003741A - Sales novedosas. - Google Patents
Sales novedosas.Info
- Publication number
- MX2020003741A MX2020003741A MX2020003741A MX2020003741A MX2020003741A MX 2020003741 A MX2020003741 A MX 2020003741A MX 2020003741 A MX2020003741 A MX 2020003741A MX 2020003741 A MX2020003741 A MX 2020003741A MX 2020003741 A MX2020003741 A MX 2020003741A
- Authority
- MX
- Mexico
- Prior art keywords
- salts
- novel salts
- methyl
- novel
- diazaspiro
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 4
- GCZUIPVRHLYYOG-UHFFFAOYSA-N 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one Chemical class O=C1N(C)CCC11NC(C=2N=C(C=C(C)N=2)C=2C=CC(=CC=2)C(F)(F)F)CC1 GCZUIPVRHLYYOG-UHFFFAOYSA-N 0.000 abstract 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 abstract 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invencion hace referencia a sales novedosas de 7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]pirimidin-2-il]-1, 7-diazaespiro[4.4]nonan-6-ona, a composiciones que contienen dichas sales y al uso de dichas sales en el tratamiento de enfermedades y afecciones mediadas por la modulacion de canales de sodio regulados por voltaje.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762564744P | 2017-09-28 | 2017-09-28 | |
| PCT/US2018/053520 WO2019067961A1 (en) | 2017-09-28 | 2018-09-28 | NEW SALTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003741A true MX2020003741A (es) | 2021-01-08 |
Family
ID=65902742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003741A MX2020003741A (es) | 2017-09-28 | 2018-09-28 | Sales novedosas. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200255438A1 (es) |
| EP (1) | EP3687533A4 (es) |
| JP (1) | JP2020536070A (es) |
| KR (1) | KR20200060404A (es) |
| CN (1) | CN111343978A (es) |
| AU (2) | AU2018338884A1 (es) |
| BR (1) | BR112020005992A2 (es) |
| CA (1) | CA3074923A1 (es) |
| EA (1) | EA202090853A1 (es) |
| IL (1) | IL273520A (es) |
| MA (1) | MA50669A (es) |
| MX (1) | MX2020003741A (es) |
| SG (1) | SG11202002200UA (es) |
| WO (1) | WO2019067961A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020536898A (ja) | 2017-10-10 | 2020-12-17 | バイオジェン インコーポレイテッド | スピロ誘導体を調製するためのプロセス |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013519732A (ja) * | 2010-02-17 | 2013-05-30 | アムジエン・インコーポレーテツド | 疼痛治療のためのナトリウムチャンネル阻害薬としてのアリールカルボキサミド誘導体 |
| JP2015525202A (ja) * | 2012-05-03 | 2015-09-03 | ノバルティス アーゲー | グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態 |
| GB201209015D0 (en) * | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
-
2018
- 2018-09-28 JP JP2020518078A patent/JP2020536070A/ja not_active Withdrawn
- 2018-09-28 MA MA050669A patent/MA50669A/fr unknown
- 2018-09-28 MX MX2020003741A patent/MX2020003741A/es unknown
- 2018-09-28 WO PCT/US2018/053520 patent/WO2019067961A1/en not_active Ceased
- 2018-09-28 SG SG11202002200UA patent/SG11202002200UA/en unknown
- 2018-09-28 CN CN201880063113.2A patent/CN111343978A/zh not_active Withdrawn
- 2018-09-28 AU AU2018338884A patent/AU2018338884A1/en not_active Abandoned
- 2018-09-28 BR BR112020005992-7A patent/BR112020005992A2/pt not_active Application Discontinuation
- 2018-09-28 US US16/651,577 patent/US20200255438A1/en not_active Abandoned
- 2018-09-28 EA EA202090853A patent/EA202090853A1/ru unknown
- 2018-09-28 KR KR1020207009445A patent/KR20200060404A/ko not_active Withdrawn
- 2018-09-28 EP EP18861356.6A patent/EP3687533A4/en not_active Withdrawn
- 2018-09-28 CA CA3074923A patent/CA3074923A1/en not_active Withdrawn
-
2020
- 2020-03-23 IL IL273520A patent/IL273520A/en unknown
-
2023
- 2023-04-13 AU AU2023202293A patent/AU2023202293A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3687533A4 (en) | 2021-01-20 |
| CA3074923A1 (en) | 2019-04-04 |
| EP3687533A1 (en) | 2020-08-05 |
| AU2018338884A1 (en) | 2020-04-16 |
| AU2023202293A1 (en) | 2023-05-11 |
| BR112020005992A2 (pt) | 2020-09-29 |
| KR20200060404A (ko) | 2020-05-29 |
| JP2020536070A (ja) | 2020-12-10 |
| WO2019067961A1 (en) | 2019-04-04 |
| EA202090853A1 (ru) | 2020-08-27 |
| IL273520A (en) | 2020-05-31 |
| CN111343978A (zh) | 2020-06-26 |
| SG11202002200UA (en) | 2020-04-29 |
| MA50669A (fr) | 2020-08-05 |
| US20200255438A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121170T1 (el) | Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων | |
| PA8772101A1 (es) | Imidazol-triazolopirimidinas sustituidas | |
| CY1119766T1 (el) | Νεοι ρυθμιστες κινασης βενζοπυρανιου | |
| HN2005000795A (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2 | |
| UY36371A (es) | Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec | |
| CL2018000292A1 (es) | Compuestos farmacéuticos | |
| CL2017003402A1 (es) | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo | |
| HN2006018410A (es) | Nuevos derivados del fluoreno, composiciones que los contienen y utilizacion | |
| MX2019014514A (es) | Compuestos para tratar la enfermedad de huntington. | |
| PE20210115A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| EA202091324A1 (ru) | Комбинация 4-пиримидинсульфамидного производного с ингибитором sglt-2 для лечения заболеваний, связанных с эндотелином | |
| MX2018015252A (es) | Inhibidores de la interaccion de menina-leucemia de linaje mixto. | |
| ECSP099357A (es) | COMPUESTOS QUE MODULAN ACTIVIDAD C-FMS y/o C-KIT Y USOS PARA ELLO | |
| ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| UY37098A (es) | Moduladores de ror-gamma | |
| BR112014030655A8 (pt) | Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende | |
| BR112016025423A2 (pt) | compostos e composições como agonistas de receptores do tipo toll 7 | |
| BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| MX2018008815A (es) | Inhibidores de tirosina quinasa de bruton. | |
| BR112015003655A2 (pt) | composto; uso de um composto; e composição farmacêutica | |
| ECSP17010481A (es) | Novedosas pirimidinas 2,5-sustituidas | |
| UY36145A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| PE20181287A1 (es) | Ciano tienotriazolpirazinas y usos de las mismas |